Detection of NSCLC-derived mutant RNA in platelets

血小板中 NSCLC 衍生突变 RNA 的检测

• 批准号: 8692700
• 负责人: BAKHOS A TANNOUS
• 金额: $ 18.35万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8692700
• 关键词: Accounting; Biological Assay; Biological Markers; Biopsy; Blood Platelets; Cancer Etiology; Cancer Patient; Cessation of life; Clinical; Data; Detection; Development; Diagnostic; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Erlotinib; Exons; Formalin; Gefitinib; Growth; KRAS2 gene; Laboratories; Malignant - descriptor; Malignant neoplasm of lung; Methods; Mutation; Mutation Detection; Non-Small-Cell Lung Carcinoma; Nucleic Acids; Paraffin Embedding; Pathology Report; Patients; RNA; Serum; Signal Pathway; Source; Staging; Survival Rate; Technology; Time; Tumor-Derived; Woman; base; cancer type; extracellular; improved; meetings; men; mutant; novel; public health relevance; response; therapy development; tumor

DESCRIPTION (provided by applicant): Non-small cell lung carcinoma (NSCLC) accounts for about 87% of all lung cancer, the leading cause of cancer-related death for men and women with an overall 5 year survival rate of 10-15%. Efforts to improve the survival of NSCLC patients are currently focused on the development of new target-based therapies directed against key signaling pathways involved in lung cancer growth and malignant progression. A successful example of this approach has been the development of therapies targeting the epidermal growth factor receptor (EGFR) in NSCLC. Patients with EGFR activating mutations (which account for about 10%-15% of NSCLC) receive tremendous benefit from EGFR tyrosine kinase inhibitor therapy and are thought to represent the majority of patients who benefit from EGFR-directed therapies. Patients with tumors containing Exon 19 EGFR mutations have longer survival time following treatment. One of the main barriers to these targeted therapies is obtaining easily accessible high-quality nucleic acids for diagnostic analysis. Recently, our collaborator showed that thrombocytes (platelets) can be used as a novel source of high-quality tumor-derived (mutant) RNAs. This intriguing finding meets current requirements for diagnostics since the method is easy, non-invasive and suitable for detecting tumor-derived RNAs in various cancer types. In this study, we will explore blood platelets as a source for detection of NSCLC predictive/responsive biomarkers.

描述（由申请人提供）：非小细胞肺癌（NSCLC）约占所有肺癌的87%，是男性和女性癌症相关死亡的主要原因，总体5年生存率为10- 15%。 提高NSCLC患者生存率的努力目前集中在开发针对肺癌生长和恶性进展中涉及的关键信号通路的新靶向治疗。 这种方法的一个成功例子是开发了靶向NSCLC中表皮生长因子受体（EGFR）的疗法。 携带EGFR激活突变的患者（约占NSCLC的10%-15%）从EGFR酪氨酸激酶抑制剂治疗中获益巨大，被认为代表了大多数从EGFR靶向治疗中获益的患者。 携带EGFR 19号外显子突变的肿瘤患者在治疗后的生存时间较长。 这些靶向治疗的主要障碍之一是获得易于获得的高质量核酸用于诊断分析。 最近，我们的合作者表明，血小板（血小板）可用作高质量肿瘤衍生（突变）RNA的新来源。 这一有趣的发现满足了当前的诊断要求，因为该方法简单，非侵入性，适用于检测各种癌症类型中的肿瘤衍生RNA。 在这项研究中，我们将探索血小板作为检测NSCLC预测/反应生物标志物的来源。